AngioDynamics

389 articles about AngioDynamics

• AngioDynamics Awarded Premier’s Nationally Outsourced Implantable Infusion Port Agreement

  9/9/2019

  AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that the Company has been awarded a dual-source group purchasing agreement by Premier, Inc. to supply implantable infusion ports.

• AngioDynamics to Report Fiscal 2020 First Quarter Financial Results on October 3, 2019

  9/5/2019

  The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

• AngioDynamics Announces Appointment of Former Johnson & Johnson Executive Karen Licitra to its Board of Directors

  7/31/2019

  AngioDynamics, Inc., a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, announced the appointment of Karen Licitra to its board of directors as a Class III director, effective July 17, 2019.

• AngioDynamics to Present at the Canaccord Genuity Growth Conference

  7/23/2019

  AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, will present at the 39th Annual Canaccord Genuity Growth Conference at 10:30 a.m. ET on Wednesday, August 7, 2019 in Boston, MA.

• AngioDynamics Reports Fiscal 2019 Fourth Quarter and Full-Year Financial Results

  7/10/2019

  AngioDynamics, Inc. announced financial results for the fourth quarter of fiscal year 2019, which ended May 31, 2019.

• AngioDynamics to Report Fiscal 2019 Fourth Quarter and Full-Year Financial Results on July 10, 2019

  6/20/2019

  AngioDynamics, Inc. announced that it will report financial results for the fourth quarter and fiscal year 2019 before the market open on Wednesday, July 10, 2019.

• AngioDynamics to Present at the Raymond James Life Sciences and MedTech Conference

  6/4/2019

  AngioDynamics, Inc. announced that Jim Clemmer, President and Chief Executive Officer, will present at the Raymond James Life Sciences and MedTech Conference at 1:50 p.m. ET on Tuesday, June 18, 2019 in New York, NY.

• AngioDynamics Completes Sale of NAMIC® Fluid Management Portfolio to Medline Industries, Inc.

  6/3/2019

  AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it closed the previously announced sale of its NAMIC® fluid management portfolio to Medline Industries, Inc. on May 31, 2019 for $167.5 million.

• AngioDynamics Receives FDA Approval to Initiate Pilot Study for the Use of NanoKnife® to Treat Prostate Cancer

  5/22/2019

  The prospective, non-randomized pilot study includes six subjects at up to three clinical sites.

• AngioDynamics Announces First Patient Enrolled in NanoKnife® DIRECT Clinical Study for the Treatment of Stage III Pancreatic Cancer

  5/13/2019

  AngioDynamics, Inc. announced enrollment of the first patient in its NanoKnife® Irreversible Electroporation “Data IRE Cancer Treatment” clinical study.

• AngioDynamics Announces Agreement to Sell NAMIC® Fluid Management Business to Medline Industries, Inc. for $167.5 Million

  4/17/2019

  AngioDynamics to host conference call at 5:00 p.m. ET

• AngioDynamics’ DIRECT Clinical Study Receives Institutional Review Board Approval for the Treatment of Stage III Pancreatic Cancer

  4/17/2019

  AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that the Company received central Institutional Review Board (IRB) approval to conduct its NanoKnife® Irreversible Electroporation “Direct IRE Cancer Treatment” clinical study (DIRECT).

• AngioDynamics to Present at the Needham Healthcare Conference

  4/1/2019

  AngioDynamics, Inc. announced that Michael C. Greiner, Executive Vice President and Chief Financial Officer, will present at the 18th Annual Needham Healthcare Conference at 1:30 p.m. ET on Tuesday, April 9, 2019 in New York, NY.

• AngioDynamics Receives FDA Approval to Initiate NanoKnife® DIRECT Clinical Study for the Treatment of Stage III Pancreatic Cancer

  4/1/2019

  AngioDynamics, Inc. announced that the United States Food and Drug Administration approved the Company’s investigational device exemption application for its NanoKnife® Irreversible Electroporation “Direct IRE Cancer Treatment” clinical study.

• CORRECTING and REPLACING OARtrac® Radiation Dose Monitoring System Receives Expanded FDA Clearance for Electron Radiation Therapy

  3/28/2019

  AngioDynamics, Inc. announced that the United States Food and Drug Administration (FDA) granted an expanded 510(k) clearance for the OARtrac Radiation Dose Monitoring System.

• OARtrac® Radiation Dose Monitoring System Receives Expanded FDA Clearance for Electron Radiation Therapy

  3/28/2019

  The OARtrac System allows clinicians to measure and validate radiation doses targeted to a specific area of a patient’s body, allowing for more accurate and informed dosing.

• AngioDynamics to Report Fiscal 2019 Third Quarter Financial Results on April 2, 2019

  3/12/2019

  AngioDynamics, Inc., a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, announced that it will report financial results for the third quarter of fiscal year 2019 before the market open on Tuesday, April 2, 2019.

• AngioDynamics Wins Patent Infringement Dispute With Bard

  3/8/2019

  AngioDynamics, Inc. announced that the United States District Court for the District of Delaware, on day four of a jury trial at the close of C.R. Bard’s case, granted judgement as a matter of law under rule 50 in favor of AngioDynamics, dismissing Bard’s suit alleging that certain of AngioDynamics’ implantable port products infringed three Bard patents.

• AngioDynamics to Present at the Barclays Global Healthcare Conference on March 13, 2019

  2/26/2019

  AngioDynamics, Inc. announced that Jim Clemmer, President and Chief Executive Officer, and Michael C. Greiner, Executive Vice President and Chief Financial Officer, will present at the Barclays Global Healthcare Conference at 4:20 p.m. ET on Wednesday, March 13, 2019 in Miami Beach, FL.

• AngioDynamics Reports Fiscal 2019 Second Quarter Financial Results

  1/4/2019

  Fiscal 2019 Second Quarter Highlights